Stoke Therapeutics, Inc.
STOK
Rank in Stocks
#6249
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to... Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Share Price
$26.68
Last synced: 2026-11-13
Market Cap
$1.82B
Change (1 day)
1.83%
Change (1 year)
0.64%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Stoke Therapeutics, Inc. (STOK)
Category
Healthcare
EPS for Stoke Therapeutics, Inc. (STOK)
EPS as of September 2026 TTM: $-3.79
According to Stoke Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-3.79. At the end of 2025 the company had an EPS of $-0.12, an increase over its 2024 EPS of $-1.65.
EPS history for Stoke Therapeutics, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.79 | 3,058.33% |
| 2025 | $-0.12 | -92.73% |
| 2024 | $-1.65 | -30.67% |
| 2023 | $-2.38 | -8.46% |
| 2022 | $-2.60 | 11.11% |
| 2021 | $-2.34 | 50.00% |
| 2020 | $-1.56 | -1.89% |
| 2019 | $-1.59 | 200.00% |
| 2018 | $-0.53 | 120.83% |
| 2017 | $-0.24 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | -76.52% |
US
|
|
| $15.66 | -513.19% |
US
|
|
| $-7.07 | 86.54% |
US
|
|
| $-5.29 | 39.58% |
AU
|
|
| $12.73 | -435.94% |
BE
|
Questions about Stoke Therapeutics, Inc.'s earnings per share (EPS)
What is Stoke Therapeutics, Inc.'s earnings per share (EPS)?
Stoke Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-3.79, as of Sep 2026.
What was Stoke Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Stoke Therapeutics, Inc.'s earnings per share (EPS) was $-0.12, compared with $-1.65 in 2024.
How has Stoke Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Stoke Therapeutics, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.12) and lowest in 2022 ($-2.60).
How does Stoke Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Stoke Therapeutics, Inc.'s earnings per share (EPS) ($-3.79) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.